Canadian Respiratory Journal / 2016 / Article / Tab 2

Research Article

The Characteristics of Treated Pulmonary Arterial Hypertension Patients in Ontario

Table 2

Overall and age-stratified PAH drug therapy utilization patterns in Ontario between April 1, 2011, and March 31, 2012.

PAH drug therapyOverall
Age < 65
Age ≥ 65
value
Age < 65 versus age ≥ 65
(%) (%) (%)

Overall single therapy 232 (77.1%)118 (77.6%)114 (76.5%)0.817
Overall combination therapy 69 (22.9%)34 (22.4%)35 (23.5%)0.817
Types of single therapy
 PDE5 inhibitors66 (28.4%)23–28 (19–24%)40–45 (35–39%)0.013
 ERA140 (60.3%)65–70 (55–59%)70–75 (61–66%)0.389
 Prostanoids26 (11.2%)21–26 (20–22%)≤5 (0–4%)<0.001
Types of combination therapy
 PDE5 inhibitors + ERA62 (89.9%)28–33 (82–97%)29–34 (83–97%)0.661

Ranges provided for privacy reasons to avoid reidentification of small cell sizes.
Note: 25 out of 326 patients did not have a subsequent PAH prescription over the follow-up period, despite having a past PAH prescription, and therefore are excluded from this analysis.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.